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ABSTRACT
With rapid advances in our understanding of cancer, there
is an expanding number of potential novel combination
therapies, including novel–novel combinations. Identifying
which combinations are appropriate and in which
subpopulations are among the most difficult questions in
medical research. We conducted a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA)-guided systematic review of trials of novel–novel
combination therapies involving immunotherapies or
molecular targeted therapies in advanced solid tumors.
A MEDLINE search was conducted using a modified
Cochrane Highly Sensitive Search Strategy for published
clinical trials between July 1, 2017, and June 30, 2020,
in the top-ranked medical and oncology journals. Trials
were evaluated according to a criterion adapted from
previously published Food and Drug Administration
guidance and other key considerations in designing trials
of combinations. This included the presence of a strong
biological rationale, the use of a new established or
emerging predictive biomarker prospectively incorporated
into the clinical trial design, appropriate comparator arms
of monotherapy or supportive external data sources and
a primary endpoint demonstrating a clinically meaningful
benefit. Of 32 identified trials, there were 11 (34%) trials
of the novel–novel combination of anti-programmed
death 1 (PD-1)/programmed death ligand 1 (PD-L1) and
anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4) therapy, and 10 (31%) trials of anti-PD-1/PD-L1 and
anti-vascular endothelial growth factor (VEGF) combination
therapy. 20 (62.5%) trials were phase II trials, while 12
(37.5%) were phase III trials. Most (72%) trials lacked
significant preclinical evidence supporting the development
of the combination in the given indication. A majority of
trials (69%) were conducted in biomarker unselected
populations or used pre-existing biomarkers within the
given indication for patient selection. Most studies (66%)
were considered to have appropriate comparator arms or
had supportive external data sources such as prior studies
of monotherapy. All studies were evaluated as selecting
a clinically meaningful primary endpoint. In conclusion,
designing trials to evaluate novel–novel combination
therapies presents numerous challenges to demonstrate
efficacy in a comprehensive manner. A greater

understanding of biological rationale for combinations
and incorporating predictive biomarkers may improve
effective evaluation of combination therapies. Innovative
statistical methods and increasing use of external data to
support combination approaches are potential strategies
that may improve the efficiency of trial design. Designing
trials to evaluate novel–novel combination therapies
presents numerous challenges to demonstrate efficacy
in a comprehensive manner. A greater understanding of
biological rationale for combinations and incorporating
predictive biomarkers may improve effective evaluation of
combination therapies. Innovative statistical methods and
increasing use of external data to support combination
approaches are potential strategies that may improve the
efficiency of trial design.

INTRODUCTION
With rapid advances in our understanding
of cancer genomics and immunobiology, an
expanding number of novel therapies are
being evaluated in clinical trials.1 As a consequence, there is an exponentially increasing
number of mathematically possible drug
combinations,2 including novel–novel combinations, in which two or more drugs are
investigational and are not yet approved standards of care. Concordantly, there has been
an increase in the number of clinical trials
evaluating combination therapies.3 The use
of combination therapies to improve efficacy has traditionally been a central tenet
of medical oncology ever since the initial
use of combination chemotherapy regimens
in hematological malignancies and breast
cancer.4 The underlying rationale is anchored
in the synergistic or additive effects of drugs
with differing and potentially complementary
mechanisms of action to increase the likelihood of response, forestall or overcome resistance and minimize overlapping toxicities.
However, patient-
to-
patient variability and
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Association, Lancet Oncology, Journal of Clinical Oncology,
Cancer Discovery, JAMA Oncology, and Annals of Oncology).
These journals were selected as the top-ranked general
medical or general oncology journals by impact factor
that publish oncology clinical trials according to the
Journal Citation Reports 2019.

METHODS
Search strategy
The search strategy was conducted in MEDLINE
according to a modified Cochrane Highly Sensitive
Search Strategy to identify published clinical trials that
evaluated novel combination therapies in advanced solid
tumors. In order to maintain contemporary relevance
and focus on the most innovative/promising agents, our
search covered the time period from July 1, 2017, to June
30, 2020, and was restricted to articles published in eight
selected high-
tier peer-
reviewed journals (New England
Journal of Medicine, Lancet, Journal of the American Medical

Study evaluation and statistical analysis
The trial design of each study was evaluated according
to a set of criteria adapted from the criteria outlined by
the FDA in their guidance on the development of novel
combination therapies.7 As this review consisted only of
studies involving patients with advanced cancer, it was
accepted that all studies fulfilled the first FDA criteria, in
that studies were evaluating a combination treatment for
a serious disease or condition. Further general criteria in
the FDA guidance included (1) a strong biological rationale for use of the combination and (2) the combination may provide a significant therapeutic advance over

2
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Study selection
A priori inclusion criteria were established. To be eligible
for inclusion, studies had to be primary research articles reporting the outcomes of a phase II or III clinical
trial evaluating novel–novel combination therapy with
programmed death 1 (PD-1)/programmed death ligand
1 (PD-L1) or cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) immune checkpoint targeting agents or molecularly targeted agents. Novel–novel combination therapy
was defined as two or more investigational drugs, of which
none were approved or recommended by treatment
guidelines for the given indication. Exclusion criteria
included pediatric studies (subjects<18 years of age),
observational studies, meta-analyses, publications using
pooled data from two or more trials, dose finding or phase
I trials, early stage or locally advanced solid tumor studies,
and hematological studies. In cases of updated analyses
after initial study publication, studies were included in
this analysis only if prespecified additional analysis for
mature data of primary endpoints was being reported.
Board-certified or equivalent oncologists (ACT and MK)
reviewed the articles for final eligibility, and disagreement
was resolved by discussion and consensus.
Data extraction
Data extracted for each study included (1) study name/
clinical trial ID; (2) journal; (3) authors; (4) trial sponsor;
(5) tumor type and study population (newly diagnosed
vs recurrent); (6) drugs studied; (7) treatment arms;
(8) trial phase; (9) treatment regimens; (10) Common
Terminology Criteria for Adverse Events version used;
(11) biomarker selection criteria; (12) trial endpoints;
(13) response data including objective response rate
(ORR); (14) survival data including progression-
free
survival (PFS) and overall survival (OS); (15) adverse
event data, including number of total and severe adverse
events and mortality; (16) FDA approval for the combination therapy as of September 2020.
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the independent action of drugs may also confer benefit
for combination therapies without additive or synergistic
interactions.5
Multiarm, ‘pick-
the-
winner’ or factorial trial designs
may often be used to evaluate more than one novel treatment individually and in combination in a single trial.6
However, it may be impractical to conduct such trials
due to finite resources, particularly with an increasing
number of novel therapies and potential combinations.
Identifying which combinations are appropriate in which
patient subpopulations are among the most difficult questions in medical research. Garnering regulatory approval
requires demonstrating that each component of a combination contributes to its benefit. This creates numerous
challenges for clinicians, industry and regulatory bodies
alike in designing, conducting and interpreting trials
of novel–novel combination therapies. Therefore, the
rational, efficient and effective evaluation of novel–novel
drug combinations is crucial. Regulatory agencies, such
as the US Food and Drug Administration (FDA), have
recognized these challenges and have released formal
guidance for trial sponsors.7 Nevertheless, a fine balance
between the level of evidence required to obtain regulatory approval of a novel–novel combination versus the
practicality of conducting such trials is needed. Furthermore, as the drug development landscape in oncology
continues to evolve, such as the advent of immunotherapeutic strategies, capabilities to adapt clinical trial design
remain crucial.8
We sought to conduct a focused systematic review of clinical trials of novel–novel combination therapies involving
immunotherapies or molecular targeted therapies in
advanced solid tumors in order to identify opportunities
to improve paradigms for the drug development pathway
and clinical trial evaluation of the efficacy of rational
combination therapies. Selected studies were evaluated
and assessed according to a set of criteria adapted from
the aforementioned FDA guidance and other key considerations in designing trials of novel–novel combination
therapies. This included the underlying biological rationale for the combination, the incorporation of an established or emerging predictive biomarker, and the clinical
trial design in terms of comparator arms and the primary
endpoint.

Open access

Figure 1
inhibitor.

4. Primary endpoint which demonstrates a clinically
meaningful benefit in the given indication and according to the phase of trial, such as ORR, PFS and/
or OS.
RESULTS
Study selection and characteristics
We identified 160 potentially eligible studies. After full-
text review and applying the selection criteria, 32 studies
were included in the final analysis (figure 1). The characteristics of the studies are listed in table 1. Studies were
broadly classified based on the drug–target combination
for further in-depth analysis according to the evaluation
criteria (see online supplemental appendix for additional
results).
Inhibition of PD-1/PD-L1 and CTLA-4 combination therapy
There were 11 trials of the novel–novel combination of
anti-
PD-1/PD-
L1 and anti-
CTLA-4 therapy, as shown
in figure 2, table 2 and online supplemental appendix,
including six (55%) phase II and five (45%) phase III
trials. There were four studies conducted in non-small
cell lung cancer (NSCLC), with a range of other tumor
types in the remaining studies (figure 2).

Selection of studies evaluating a novel–novel combination therapy with a targeted therapy and/or immune checkpoint
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available therapy and is superior to the individual agents.
In addition, factors which contribute to the efficiency of
trial design and subsequent clinical impact, such as the
use of external data sources and clinically meaningful
primary endpoints, were also evaluated.
Trial designs were assessed according to the following
criteria:
1. A strong biological rationale, defined as any published
in vitro or in vivo preclinical data demonstrating activity specifically for the combination therapy with
class-specific agents over the individual agents alone
in the given indication. The presence of a biological
rationale was considered ‘limited’ if published preclinical data were conducted only in a single experimental
model system.
2. Use of a new established or emerging predictive biomarker prospectively incorporated into the clinical
trial design to define eligible patients for the combination therapy and for which there are no approved
or recommended therapeutic options for the given
biomarker.
3. Appropriate comparator arms where applicable, allowing for an evaluation of the efficacy and safety of the
individual agents alone, or supportive external data
sources such as prior studies of monotherapy.

Open access
Continued

Characteristics (n=32)

n (%)

Trial phase
 II

20 (62.5)

Primary endpoint

 III

12 (37.5)

 Phase II trials (n=36)

Trial sponsor

Characteristics (n=32)

n (%)

 Unselected

17 (53)

 ORR

15 (75)

 Academic

10 (31)

 PFS

3 (15)

 Industry

22 (69)

 OS

1 (5)

 DCR

1 (5)

Tumor type
 Breast

1 (3)

 Phase III trials (n=12)

 Colorectal

4 (13)

 PFS

2 (17)

 Endometrial

1 (3)

 HCC

1 (3)

 OS
 PFS and OS

3 (25)
6 (50)

 HNSCC

1 (3)

 Melanoma

1 (3)

 Mesothelioma

1 (3)

 Multiple, including basket

2 (6)

 NSCLC

5 (16)

 Ovarian

2 (6)

 Pancreatic

1 (3)

 RCC

7 (22)

 Salivary

1 (3)

 Sarcoma

3 (9)

 Thyroid

1 (3)

*Chemotherapy+VEGF, chemotherapy+PARP, PD-1+HPV16
vaccine, PD-1+oncolytic virus, PD-L1+MEK.
CTLA-4, cytotoxic T lymphocyte-associated antigen-4; DCR,
disease control rate; EGFR, epidermal growth factor receptor;
HCC, hepatocellular carcinoma; HER2, human epidermal
growth factor receptor 2; HNSCC, head and neck squamous
cell carcinoma; JAMA, The Journal of the American Medical
Association; MEK, mitogen-activated protein kinase kinase;
NSCLC, non-small cell lung cancer; ORR, objective response rate;
OS, overall survival; PARP, poly(ADP-ribose) polymerase; PD-1,
programmed death 1
; PD-L1, programmed death ligand 1
; PFS, progression-free survival; RCC, renal cell carcinoma; VEGF,
vascular endothelial growth factor.

Journal
 
Annals of Oncology
 
 
Cancer Discovery

4 (13)
0 (0)

 
JAMA

0 (0)

 
JAMA Oncology

7 (22)

 
Journal of Clinical Oncology

5 (16)

 
Lancet

1 (3)

 
Lancet Oncology

8 (25)

 
New England Journal of
Medicine

7 (22)

Combination therapy
 Immunotherapy
 Targeted therapy
 Both immunotherapy and
targeted therapy

13 (41)
8 (25)
11 (34)

Drug targets
 PD-1/PD-L1+CTLA-4

11 (34)

 PD-1/PD-L1+VEGF

10 (31)

 BRAF+MEK (±EGFR)

4 (13)

 HER2

2 (6)

 Other*

5 (16)

Biomarker selection
 Selected

15 (47)
Continued

4

Rationale for combinations
We first assessed for the presence of a strong biological rationale for the combination approach, according
to preclinical data supporting superior efficacy of the
combination compared with the individual agents alone,
in the given indication. The combination of nivolumab
and ipilimumab was first approved in unresectable or
metastatic melanoma in 2015, while there is currently no
approved indication for the combination of durvalumab
and tremelimumab. Preclinical models in melanoma
demonstrated the enhanced antitumor activity for
combination checkpoint blockade,9 and development
of the combination was also supported by synergistic
activity observed in murine colorectal and ovarian tumor
models.10 11 Anti-CTLA-4 therapy impacts the lymphoid
compartment, resulting in an increase in the number as
well as breadth of specificity of tumor antigen reactive
T cells, whereas anti-PD-1 impacts the immunosuppression within the tumor microenvironment. Clinical activity
was subsequently seen in a phase I trial of nivolumab
and ipilimumab in patients with advanced melanoma.12
As a result, trials of combination checkpoint blockade
were evaluated in numerous other cancers. Of the 11
trials investigating inhibition of PD-1/PD-L1 and CTLA-4
combination therapy included in this review, there was a
distinct absence of a strong biological rationale in most
studied indications, with limited in vitro or in vivo data
supporting the combination, although in many cases
Tan AC, et al. J Immunother Cancer 2021;9:e002459. doi:10.1136/jitc-2021-002459
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Table 1

Table 1 Study characteristics

Open access

there were preliminary signs of efficacy in early-phase
trials, including phase I trials, emphasizing the need for
better preclinical models to select rational combination
immunotherapy approaches.13
Utility of biomarkers
Next, we assessed the incorporation of a newly established
or emerging predictive biomarker into the trial design
that may suggest efficacy of the combination superior to
monotherapy. Of the 11 trials, 6 (55%) were conducted in
unselected patient populations. Four (44%) trials selected
patients based on PD-L1 status, a previously established
but somewhat controversial biomarker to select patients
for anti-PD-1/PD-L1 monotherapy. Only one (9%) trial
incorporated a new established or emerging biomarker,
with the CheckMate 227 trial including a coprimary
endpoint of PFS in patients with high tumor mutation
burden (TMB) for nivolumab plus ipilimumab versus
chemotherapy.14
Comparator arms
The use of appropriate comparator arms that would allow
for the comparison of the efficacy and safety of the individual agents alone versus the combination was also critically examined. This was evaluated in the context of the
presence or absence of supportive external data sources,
such as prior studies of monotherapy. Of the phase III
trials, one trial was conducted in first-line renal cell carcinoma (RCC), with the remaining trials conducted in
NSCLC. CheckMate 214 evaluated nivolumab plus ipilimumab versus sunitinib as first-line therapy in advanced
RCC.15 There was prior monotherapy data for ipilimumab in a phase II trial that allowed pretreated and treatment naïve patients.16 Nivolumab monotherapy, already
approved in the treatment resistant setting,17 had also
been evaluated in treatment-naïve patients in a multicohort phase Ib expansion study.18 CheckMate 227 was
an open-label phase III randomized trial in untreated
advanced NSCLC.14 19 The trial was designed to test
multiple nivolumab-based regimens in different patient
populations. Nivolumab monotherapy had been previously evaluated in treatment-naïve advanced NSCLC in
the phase III CheckMate 026 study in patients with PD-L1
expression of 5% or more,20 while ipilimumab monotherapy had been evaluated in a previous phase II trial.21
Durvalumab plus tremelimumab was evaluated in two
Tan AC, et al. J Immunother Cancer 2021;9:e002459. doi:10.1136/jitc-2021-002459

phase III trials for NSCLC, with the MYSTIC trial22 as first-
line therapy and the ARCTIC trial23 as third-line or later
line therapy. Durvalumab monotherapy had been investigated in the treatment-refractory setting in NSCLC,24 but
neither durvalumab or tremelimumab monotherapy had
been previously evaluated in the first-line setting.
Overall, the phase II and III trials of combination anti-
PD-1/PD-L1 and anti-CTLA-4 therapy were appropriately
designed with comparator arms of either individual agent
alone and where there were no prior studies in the given
indication.
Primary endpoints
The primary endpoints of the selected studies were also
evaluated. In general, the phase II studies used ORR or
DCR, while the phase III studies used PFS and/or OS.
The primary endpoints were assessed overall as appropriate and clinically meaningful in all studies.
Inhibition of PD-1/PD-L1 and VEGF combination therapy
There were 10 trials of the novel–novel combination of
anti-
PD-1/PD-
L1 and anti-
vascular endothelial growth
factor (VEGF) therapy, as shown in figure 3, online
supplemental table 1 and online supplemental appendix.
Rationale for combinations
The combination of antiangiogenic therapy and immune
checkpoint inhibitor therapy is based on evidence
demonstrating that aberrant angiogenesis is a hallmark
of many solid tumors, resulting in immune evasion.25
Therefore, normalization of abnormal tumor vasculature with antiangiogenic therapy may improve immune
effector cell function by decreasing hypoxia, acidosis and
nutrient deprivation and may increase the infiltration
of immune effector cells into the tumor microenvironment in order to enhance the efficacy of immunotherapy.
VEGF also has pleotropic immunosuppressive effects
including impairment of dendritic cell function, as well
as mobilization of immunosuppressive cells such as tumor
associated macrophages, regulatory T cells, and myeloid-
derived suppressor cells.26 Consequently, this has led to
a proliferation of studies of novel–novel combinations
of therapeutics from these two classes. Improved efficacy with combination inhibition of VEGF and immune
checkpoint blockade has been shown in animal models
for melanoma,27 colorectal cancer,28 breast cancer and
5
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Figure 2 Characteristics of combination anti-PD-1/PD-L1 and anti-CTLA-4 therapy trials. (A) Combination therapy regimen,
(B) tumor type, and (C) trial phase. HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; RCC,
renal cell carcinoma.
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CONDOR

2020, Chen

2020,
Zamarin

CO.26

NRG GY003

2018,
Hellmann

2019,
Hellmann

2020, Rizvi

2020,
Planchard

CheckMate 227

CheckMate 227

MYSTIC

ARCTIC

NSCLC

NSCLC

NSCLC

NSCLC

RCC

3+

1

1

1

1

2+

3+

2

100

180

65

125

267

96

Durvalumab
plus
tremelimumab

Durvalumab
plus
tremelimumab
595

1118

Nivolumab plus 1739
ipilimumab

Nivolumab plus 1739
ipilimumab

PD-L1

Coprimary: PFS and
OS (D+T vs SOC in PD-
L1<25%)

Coprimary: OS (D vs
chemo in PD-L1≥25%),
PFS and OS (D+T vs
chemo in PD-L1≥25%)

Coprimary: OS (N+I vs
chemo in PD-L1≥1%)

PD-L1

Coprimary: OS, ORR and
PFS (in intermediate or
poor prognostic risk)

Yes

Yes

Study A: PD-
L1≥25%, D or SOC
(1:1); Study B: PD-
L1<25%, D+T or
SOC or D or T
(3:2:2:1)

D or D+T or chemo
(1:1:1)

No

No

PD-L1≥1%, N+I or N No
or chemo (1:1:1)
PD-L1<1%, N+I or
N+chemo or chemo Yes
(1:1:1)

N+I or sunitinib (1:1)

ORR at 6 months (N vs N+I) N or N+I (1:1)

D+T or BSC (2:1)

Yes

Yes

OS (D+T vs BSC)

N or N+I (1:1)
No

Coprimary: PFS (N+I vs
chemo in TMB high)

PD-L1

Yes

PD-L1<25%, D+T or Yes
D or T (2:1:1)

N or N+I (1:1)

Trial design

ORR (D+T and D)–lead-
D+T or D (1:1)
in safety study, with
expansion pending efficacy
signal, non-comparative

DCR at 12 weeks (N and
N+I)–non-comparative

ORR (D+T)–non-
comparative

ORR (N and N+I)–non-
comparative

Primary endpoint

TMB

Unselected

Unselected

Unselected

Unselected

Unselected

PD-L1

Unselected

Patients Biomarker
(total n) selection

Nivolumab plus 1096
ipilimumab

Nivolumab plus
ipilimumab

Durvalumab
plus
tremelimumab

Durvalumab
plus
tremelimumab

Nivolumab plus
ipilimumab

Durvalumab
plus
tremelimumab

Nivolumab plus
ipilimumab

Combination
regimen

Primary
endpoint
met

No

No

Yes

Yes

Yes

No

No

No

No

No

No

No

No

No

No

No

Limited

Limited

No

No

No

No

No

No

No

Yes

No

No

No

No

No

No

No

FDA-
Strong
approved biological New
therapy
rationale biomarker

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Comparator
arms of
monotherapy

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Clinically
meaningful
primary
endpoint

BSC, best supportive care; Chemo, chemotherapy; D, durvalumab; DCR, disease control rate; HNSCC, head and neck squamous cell carcinoma; I, ipilimumab; N, nivolumab; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1,
programmed death ligand 1; PFS, progression free survival; RCC, renal cell carcinoma; SOC, standard of care; T, tremelimumab; TMB, tumor mutation burden.

2018, Motzer

CheckMate 214

Ovarian

Colorectal

2019, O’Reilly Pancreatic

Phase III trials

2+

2+

Line of
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Mesothelioma 2+

HNSCC

Sarcoma

Tumor type

NCT02558894

IFCT-1501 MAPS2 2019,
Scherpereel

2018,
D’Angelo

Alliance A091401

Phase II trials

Year, lead
author

Combination anti-PD-1/PD-L1 and anti-CTLA-4 therapy trials
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Study name

Table 2
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pancreatic neuroendocrine tumors.29 Specifically, lenvatinib plus anti-
PD-1 therapy has also been evaluated
in murine hepatocellular, colorectal and melanoma
models.30 31 However, preclinical data demonstrating the
efficacy of other specific drug combinations are sparse.
For example, the combination of axitinib plus avelumab
in RCC had not been published in preclinical models,
and the rationale for the combination as first-line therapy
was based on the toxicity profile for axitinib, with lower
hepatotoxicity compared with sunitinib.32 There were
also no preclinical data published for the remaining
combination therapies in the given studied indications.
Utility of biomarkers
Of the 10 trials evaluating combination anti-PD-1/PD-L1
and anti-VEGF therapy, a majority (80%) were conducted
in biomarker unselected populations of patients. The
two (20%) trials, which included biomarker selection
criteria, selected patients on the basis of PD-L1 IHC for
avelumab33 and atezolizumab,34 respectively, in advanced
RCC. PD-L1 IHC had not been previously established as
a biomarker for patient selection for anti-PD-1/PD-L1
therapy in advanced RCC and therefore represented a
new predictive biomarker in this patient population. No
robust biomarkers for anti-VEGF therapy have been identified, and consequently, no trial attempted to select a
biomarker for this class of agents.

as limiting characteristics of immune checkpoint inhibitors and antiangiogenic inhibitors, respectively, and in
certain extracranial settings, concern regarding post-
treatment peritumoral inflammatory changes (‘pseudoprogression’) following checkpoint inhibition has been
described. These could limit the validity of ORR as an
endpoint in such studies.
Inhibition of BRAF and MEK combination therapy
There were four trials of the novel–novel combination of
BRAF and mitogen-activated protein kinase kinase (MEK)
inhibitor therapy, as shown in online supplemental table
2 and online supplemental appendix. In addition, the
BEACON CRC trial evaluated epidermal growth factor
receptor (EGFR) inhibitor therapy in combination with
BRAF and MEK inhibition.36

Primary endpoints
The primary endpoint in five of the six phase II trials
was ORR, with the remaining trial of pembrolizumab
plus axitinib in metastatic sarcoma using PFS rate at 3
months as the primary endpoint. Coprimary endpoints
of PFS and OS were used in the four phase III trials of
combination anti-
PD-1/PD-
L1 and anti-
VEGF therapy.
Overall, these endpoints were considered appropriate
and clinically meaningful. It should be borne in mind
that in tumors of the central nervous system, both pseudoprogression and pseudoresponse have been identified

Rationale for combinations
In BRAF-mutated melanoma, the combination of BRAF
and MEK-pathway inhibition had initially established clinical efficacy and tolerability compared with BRAF-inhibitor
monotherapy with two combinations (dabrafenib plus
trametinib, and vemurafenib plus cobimetinib).37 38
BRAF and MEK inhibitor combinations were originally
developed based on preclinical data demonstrating that
the combination could improve efficacy and delay the
emergence of resistance.39 40 Reactivation of the MAPK
pathway was a commonly reported mechanism of resistance to BRAF-inhibitor monotherapy.41 42 The combination of encorafenib and binimetinib was subsequently
evaluated due to the increased potency of encorafenib
compared with dabrafenib and vemurafenib, related to
a greater dissociation half-life and improved pharmacodynamics.43 Furthermore, the combination with binimetinib, which ameliorated the toxicity of encorafenib
monotherapy, allowed for high doses of encorafenib in
the combination treatment.43
The rationale for the inhibition of BRAF, MEK and
EGFR in BRAF V600E mutated colorectal cancer was
developed after extensive preclinical investigations characterizing these pathways. Rapid feedback activation
through EGFR after BRAF inhibition alone explained the
poor efficacy of BRAF monotherapy and led to the development of BRAF plus EGFR inhibitor combinations.44 45
Subsequently, the combination of BRAF and MEK inhibition to improve efficacy compared with BRAF plus EGFR
inhibition was also demonstrated preclinically.46 47
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Comparator arms
Overall, the phase II trials of combination anti-
PD-1/
PD-L1 and VEGF therapy were appropriately designed
with comparator arms of either individual agent alone
and where there were no prior studies in the given indication. Two phase III trials in patients with treatment-naïve
metastatic RCC involved axitinib combinations. Axitinib
monotherapy is approved in the second-line setting35 but
had not been previously evaluated as first-line therapy.
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Figure 3 Characteristics of combination anti-PD-1/PD-L1 and anti-VEGF therapy trials. (A) Combination therapy regimen, (B)
tumor type, and (C) trial phase. HCC, hepatocellular carcinoma; RCC, renal cell carcinoma.
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Comparator arms and primary endpoints
arm, randomized phase III
COLUMBUS was a three-
study evaluating combination encorafenib (450 mg daily
dose) plus binimetinib versus encorafenib monotherapy
(300 mg daily dose) versus vemurafenib monotherapy.48
Binimetinib monotherapy had previously been investigated in a phase II study for patients with NRAS or BRAF-
mutated melanoma.49 BEACON CRC (Binimetinib,
Encorafenib, and Cetuximab Combined to Treat BRAF-
Mutant Colorectal Cancer) was also a three-arm, randomized phase III study, with study arms consisting of triplet
therapy (encorafenib, binimetinib and cetuximab),
doublet therapy (encorafenib and cetuximab) or investigator’s choice of cetuximab plus irinotecan or cetuximab plus FOLFIRI (control group).36 There had been
no prior trials of encorafenib, binimetinib or cetuximab
monotherapy in patients with advanced BRAF V600E
mutated colorectal cancer. Cetuximab monotherapy had
previously been studied in unselected patients with metastatic colorectal cancer.50 Retrospective analyses, however,
suggested responses to cetuximab may be lower in patients
with BRAF mutations.51 Additionally, vemurafenib monotherapy had been investigated in BRAF V600E mutated
colorectal cancer in a small phase II trial and a basket
trial.52 53 There was no meaningful clinical activity for
vemurafenib monotherapy, with only one response out of
31 patients across the two trials. The primary endpoints in
COLUMBUS and BEACON CRC were both considered
clinically meaningful.

in breast cancer,58 provided a strong rationale for this
combination in HER2-amplified colorectal cancer.
Utility of biomarkers
As HER2 targeted therapies had not been approved in
either tumor type, both studies were assessed as incorporating a new established or emerging biomarker.
Comparator arms and primary endpoints
As a phase IIa multiple basket trial of various targeted
therapies in advanced solid tumors, ORR was considered
an appropriate and clinically meaningful endpoint for
the MyPathway trial. Understandably, as a basket trial,
comparator arms of either trastuzumab or pertuzumab
monotherapy were not included in this trial.

Rationale for combinations
In colorectal cancer, pre-
clinical data from HER2-
amplified colorectal tumor grafts or xenografts, had
demonstrated limited activity of single agent HER2
targeted therapy with trastuzumab, pertuzumab or lapatinib.56 57 Anti-tumor activity however, was increased with
combination HER2 targeting regimens, although with
trastuzumab plus lapatinib or pertuzumab plus lapatinib. The complementary mechanisms of action of trastuzumab and pertuzumab, and demonstrated efficacy

Other combination therapies
There were five trials evaluating other novel–novel
combination therapies, including chemotherapy plus
VEGF inhibitor therapy, chemotherapy plus poly(ADP-
ribose) polymerase (PARP) inhibitor therapy, anti-PD-1
plus HPV16 vaccine therapy, anti-PD-1 plus an oncolytic
virus therapy, and anti-PD-L1 plus MEK inhibitor therapy
(online supplemental appendix and online supplemental
table 4).
COTEZO IMblaze 370 was a three-
arm randomized
phase III study of atezolizumab plus cobimetinib versus
atezolizumab monotherapy versus regorafenib in patients
with previously treated metastatic colorectal cancer.59 In
the initial phase I trial of cobimetinib monotherapy, there
were 41 patients with metastatic colorectal cancer, but no
responses were seen.60 The combination of anti-PD-L1
and MEK inhibitor in colorectal cancer was developed on
the basis of preclinical data, suggesting MEK inhibition
could affect the immune contexture in the tumor microenvironment.61 Cobimetinib had been shown to increase
T-cell infiltration into tumors and downregulate immunosuppressive cytokines and receptors.62 Combination
therapy of cobimetininb with anti-PD-L1 inhibition also
resulted in synergistic and durable tumor regression in
mice models.62
BROCADE was a three-arm phase II trial for patients
with BRCA1/2-
mutated recurrent or metastatic breast
cancer.63 Patients were randomized to receive veliparib
plus carboplatin/paclitaxel or veliparib plus temozolomide or carboplatin/paclitaxel. The primary endpoint
was PFS comparing both veliparib containing arms with
chemotherapy alone. Veliparib plus temozolomide was
considered the novel–novel combination for this review.
Veliparib monotherapy had been evaluated in a single-arm
phase II trial for patients with germline BRCA1/2 associated metastatic breast cancer,64 while temozolomide
monotherapy had previously shown a lack of activity in an
unselected population of patients with metastatic breast
cancer.65 The rationale for the combination of temozolomide and veliparib was from preclinical breast cancer
models which demonstrated synergistic activity for the
combination.66 67 At the time the study was developed,
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Inhibition of HER2 combination therapy
There were two studies reporting the novel–novel combination of human epidermal growth factor receptor 2
(HER2) inhibitor therapy with trastuzumab and pertuzumab, as shown in online supplemental table 3 and online
supplemental appendix. Both studies were reports from
the MyPathway basket trial for patients with colorectal
cancer54 and salivary gland cancers,55 respectively.
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Utility of biomarkers
All four combination trials of BRAF plus MEK inhibition selected patients based on the presence of a BRAF
mutation. For advanced melanoma, there were already
approved therapies for patients harboring BRAF mutations. In the remaining tumor types, however, the combination therapies represented a new genotype-
directed
therapeutic option.

Open access

Discussion
With an expanding number of novel therapies in clinical development and possible drug combinations, the
fundamental challenge remains to evaluate rational
combinations efficiently and effectively. In particular, a
mechanistic understanding of the contribution of each
drug to the treatment effect is needed, both from a scientific and regulatory perspective.69 Based on a systematic
review of the top general medical and oncology journals
over the past 3 years, we identified 32 recently published
trials evaluating novel–novel combinations and evaluated
each trial according to criteria adapted from FDA guidance on the development of novel combination therapies
(box 1).
First, we assessed the strength of the biological rationale
according to the presence of published preclinical data.
Most trials (72%) lacked significant preclinical evidence
supporting the development of the combination in the
given indication. This was particularly evident in studies
evaluating combination immune checkpoint blockade,
for which there were only two studies with limited preclinical data in colorectal and ovarian cancers. This could, in
part, be attributed to difficulties in developing preclinical
animal models for immunotherapy, due to the inability of
immunocompetent animal models to fully recapitulate

the human immune system.70 Phase I studies were also
excluded from our analysis, for which preclinical data may
be especially relevant in the initial decision to evaluate a
combination. Notably, however, significant clinical efficacy
in tumor types such as NSCLC14 19 and RCC15 has been
seen, despite the lack of supportive preclinical data. For
some of these tumors (such as RCC), evidence of single
agent activity or early efficacy in phase I trials served as
the rationale for subsequent combination phase II and
III studies. Coupled with the initial outcomes of trials in
melanoma,12 this has resulted in a rapid increase in the
number of combination immunotherapy trials.3 Nevertheless, the value of numerous trials with overlap and duplication in the combination partner targets, being conducted
in unselected patients can be questioned,3 particularly in
cancers for which single-
agent immunotherapy has no
activity. This observation highlights the importance of a
greater understanding of tumor-specific immunity and the
need to develop more effective biomarkers.71 Given the
expanding number of potential combinations, rational
selection of combinations based on mechanistic evidence
and robust biological rationale is crucial.72 Additionally,
for many trials in our review, preclinical data supporting
the combination may have been demonstrated in other
tumor types outside the given trial’s studied indication.
Particularly for targeted therapies, there can be significant
diversity across tumor types in the actionability of oncogenic driver mutations.73 BRAF V600E mutations are a
prominent example, with a spectrum of activity for combination BRAF and MEK inhibition across histologies.74 This
diversity is also exemplified in colorectal cancer, with the
role for combined BRAF plus EGFR inhibition demonstrated elegantly in preclinical studies.44
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there were no targeted therapies approved for patients
BRCA1/2-mutated breast cancers.68
Overall evaluation of novel–novel combination therapies in
oncology
The overall assessment and evaluation of trial designs of
novel–novel combination therapies according to the four
criteria are shown in figure 4.
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Figure 4 Overall evaluation of novel–novel combination therapies of immune checkpoint inhibitors or molecular targeted
agents in solid tumor oncology. (A) Strong biological rationale, (B) new biomarker, (C) comparator arms of monotherapy, and (D)
clinically meaningful primary endpoint.

Open access

Summary: We searched MEDLINE according to a modified Cochrane
Highly Sensitive Search Strategy to identify published clinical trials
that evaluated novel combination therapies in advanced solid tumors.
Our search covered the period from July 1, 2017, to June 30, 2020.
We restricted our search to articles published in eight selected peer-
reviewed journals (New England Journal of Medicine, Lancet, Journal of
the American Medical Association, Lancet Oncology, Journal of Clinical
Oncology, Cancer Discovery, JAMA Oncology and Annals of Oncology).
We identified 160 potentially eligible studies. After full-text review and
applying the selection criteria, 32 studies were included in the final
analysis (figure 1). Studies were broadly classified based on the drug–
target combination for further in-depth analysis. Below is a summary of
the key messages and recommendation.
A. Key Messages
1. Combinations are the future of clinical trials and this is so in most
diseases.
2. Identifying which combinations are appropriate and in which patient subpopulations are among the most difficult questions in
medical research.
3. In 72% of the analyzed studies, there was no significant preclinical
evidence supporting the development of the specific combination
in the given indication. This was especially true in studies with
combination immune checkpoint blockade. This, in part, may be
due to difficulties in developing immunocompetent animal models
to fully recapitulate the human immune system.
4. In 69% of the analyzed studies, trial populations were unselected
and did not use pre-existing predictive biomarkers for the given
indication for patient selection.
5. Sixty-six per cent of the trials analyzed had appropriate comparator
arms or had supportive external data sources such as monotherapy prior studies.
6. A greater understanding of the biological rationale for the combination and incorporating novel biomarkers can improve the practical evaluation of novel–novel combination therapies. However,
biomarker-driven clinical trials using combination therapies present additional challenges and require careful consideration of the
biomarkers’ performance and clinical utility.
7. Actionability of oncogenic driver mutations and utility of a specific
biomarker in one cancer type does not predict similar outcomes
in other cancers, for example, EGFR in NSCLC versus CRC, TMB in
NSCLC versus gliomas. Therefore, preclinical and clinical rationales
for biomarker-driven combination therapies in one cancer cannot
justify a combination trial in another histology.
8. There were no prior activity data for monotherapy in specific tumor
cohorts in many basket trials (eg, MyPathway and ROAR).
9. Garnering regulatory approval requires demonstrating that
each component of a combination contributes to its benefit.
Such demonstrations may entail factorial designs and require
interacting closely with regulators.
10. Partial factorial designs in adaptive clinical trials are likely to
be the best and most efficient solutions for the future, especially in the context of precision medicine where biomarker-
defined subpopulations are becoming the norm.
B. Recommendations
1. Avoid duplication in partner targets in unselected patients, particularly in cancers for which single-agent immunotherapy has no
activity.
Continued
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Box 1

Continued

2. In the design of a combination, consider whether other monotherapy
arms are required when trial designs are conceived.
3. Consider if randomized arms of monotherapy are ethical; for example, if based on the mechanism of action, no clinical activity of
monotherapy is expected.
4. Consider use of milestone survival or response endpoints to more
efficiently generate early evidence.
5. Consider the incorporation of real-world evidence and novel hybrid
designs, including in regulatory decision making.
6. Consider using (historical) data on single-agent efficacy, ideally to
be obtained from multiple datasets and for all agents within the
combination.
7. Consider introducing experimental therapies, including novel–novel
combinations, into the trial at any time, allowing for rational combinations based on new biological or clinical insights.
8. Consider innovative but sound statistical methods, including
use of historical or external data sources to support combination
approaches.
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; NSCLC, non-
small cell lung cancer; TMB, tumor mutational burden.

We then evaluated the use of a newly established or
emerging predictive biomarker incorporated into the
clinical trial design. Similarly, we found that a majority
of trials (69%) were conducted in biomarker unselected
populations or used pre-
existing biomarkers within
the given indication for patient selection. No studies
included separate novel predictive biomarkers for both
novel agents. Biomarker-driven clinical trial designs and
analysis plans present additional challenges and require
careful consideration of the biomarkers’ performance
and clinical utility.75 However, the use of biomarker-
selected patients has the potential to both improve
patient care and accelerate drug development with
greater efficiency.76 CheckMate 227,14 which incorporated association of TMB with OS as a second coprimary
endpoint after an amendment prior to the initial analysis,
demonstrated the flexibility of a large phase III trial to
adapt to the emerging science. The biomarker was also
investigated as a subset of the overall trial population—
an important consideration in prospective biomarker-
driven clinical trial design. Ultimately, the role for TMB
as a predictive biomarker in NSCLC remains unclear.77
Furthermore, despite tissue agnostic approval for TMB of
≥10 as a biomarker for pembrolizumab,78 there remains
controversy over its use with numerous biological and
practical considerations across tumor types.79 80 This illustrates the difficulties in identifying predictive biomarkers,
which may lag behind the development of novel therapeutics.81 Dynamic biomarkers, which may change over time
as tumors evolve, and the cost of developing biomarkers
further complicate the development process. Nevertheless, particularly for immunotherapies, different agents
may have pleiotropic effects on a variety of different cells
and compartments where they are operational. There
may also be heterogeneity in the relative contribution of
Tan AC, et al. J Immunother Cancer 2021;9:e002459. doi:10.1136/jitc-2021-002459
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Box 1 What is specifically learned about combinations of
novel–novel agents?

Open access
and validated under this single platform master protocol.
Furthermore, experimental therapies, including novel–
novel combinations, may be introduced into the trial at any
time, allowing for rational combinations based on advances
in our biological understanding of tumors. Pharmaceutical
platforms are also increasingly using multiarm randomized trials, for example, MORPHEUS (NCT03193190,
NCT03281369, NCT03280563, NCT03424005, and
NCT03337698), with multiple combination therapy arms
compared against a single standard-of-care control arm,
and allow for the introduction of novel–novel combinations at any time.92 Additionally, seamless phase I/II trials
are becoming more commonly used93 and highlight that
many of the considerations we have outlined previously
may become increasingly important in the strategic design
of early-phase studies as well. In particular, this includes the
introduction of experimental rational combinations based
on emerging biological or clinical insights—to establish
appropriate dosing and characterize safety.
There are several limitations to our review, including the
restricted time period (July 2017–June 2020) and journal
selection, which may have introduced inherent publication
bias into the studies included in our review. However, there
were still 6/32 (19%) trials, which did not meet the primary
endpoint included, and our evaluation criteria were not
dependent on the trial’s primary outcome. In selecting only
published trials, which was required to assess our evaluation
criteria, contemporary trials such as the aforementioned
adaptive platform trials will have been excluded. Broader
evaluation of ongoing and unpublished trials is therefore
also warranted, although outside the scope of this study.
The included trials also represent the data known at the
time of initial publication, not necessarily the data known at
the time of trial design, and may therefore not completely
reveal the historical sequence of events at the time of
study conception. Ultimately though, there also needs to
be inherent flexibility to adapt to rapidly evolving clinical
paradigms. Lastly, there is significant heterogeneity of the
included trials, particularly with regard to tumor types, trial
design and mechanism of action of drug combinations.
Nevertheless, the primary focus of this review was to identify
guiding principles to improve trial efficiency in evaluating
novel–novel drug combinations. Our analysis provided key
insights into the published literature with recommendations (box 1) to improve paradigms for drug development
and future trial design.
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CONCLUSIONS
Designing trials to evaluate novel–novel combination
therapies presents numerous challenges to demonstrate efficacy in a comprehensive manner. Critically,
a greater understanding of the biological rationale for
the combination and incorporating novel predictive
biomarkers may further improve the effective evaluation of novel–novel combination therapies. Innovative
statistical methods and increasing the use of historical or external data sources to support combination
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the various elements among patients. Therefore, without
relevant biomarker selection-driven trial design, clinical
efficacy may not be gleaned with an all-comers approach.
Trial design with appropriate comparator arms of monotherapy was also assessed for each trial. Most studies (66%)
were considered to have appropriate comparator arms
or had supportive external data sources such as prior
studies of monotherapy. Noticeably, in basket trials, such
as MyPathway54 55 and ROAR (Rare Oncology Agnostic
Research),82 there were no data for monotherapy in certain
tumor cohorts. However, basket trials in rare tumor types
or uncommon molecular subsets clearly face practical
challenges in terms of statistical design and patient recruitment. This emphasizes the need for a comprehensive
understanding of tumor biology to identify optimal combinations.83 There is also increasing use and acceptance of
real-world evidence in regulatory decision making.84 Historical data on single-agent efficacy would ideally come from
multiple datasets and for all agents within the combination.85 There may also be situations in which randomized
arms of monotherapy may be unethical, for example, if
no clinical activity of monotherapy is expected based on
the mechanism of action. This heightens the importance
of careful consideration to determine whether additional
arms of monotherapy are required when trial designs are
conceived.
Finally, all studies were evaluated as selecting a primary
endpoint, which demonstrated a clinically meaningful
benefit. Nonetheless, there can be complexities in determining the validity of surrogate endpoints particularly for
early-phase combination immunotherapy trials. Milestone
survival or response endpoints are increasingly used86 to
more efficiently generate early evidence. KEYNOTE-14687
for example, had a primary endpoint of ORR at 24 weeks,
and ultimately was the basis of FDA approval for the combination of pembrolizumab plus lenvatinib in endometrial
cancer.88 This trial also provides important insights into
the use of historical data to evaluate the treatment effect
of lenvatinib and pembrolizumab monotherapy.89 90 Additional exploratory post hoc analyses using propensity score
approaches were also conducted by the FDA to evaluate the
contribution of each agent.88 Importantly though, confirmatory randomized trials evaluating the combination are
still ongoing.
Collectively, our review has identified that improvements
in the effective evaluation of novel–novel combination therapies are clearly needed. Many of these findings may also
be applicable to other combination therapies, including a
new combination of two previously approved agents or the
addition of a new agent to an existing approved therapy.
In box 1, we provide a series of recommendations on the
efficient design of future clinical trials evaluating novel
combination therapies. Novel adaptive trial designs represent one approach that may enhance the efficiency of
trials. GBM AGILE, a phase II/III adaptive platform trial
(NCT03970447), is an example which incorporates statistical
innovations such as Bayesian Adaptive design in a seamless
registration trial.91 Candidate biomarkers may be identified
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